J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks.
comments(0)
5-min edit window · permanent after that